XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2

COMMITMENTS AND CONTINGENCIES - Contingencies Related to Stanford and Merger Agreement (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2023	Feb. 28, 2023	Mar. 31, 2024	Mar. 31, 2023	Jan. 31, 2024	Nov. 15, 2021	Oct. 31, 2019
Other Commitments
Contingent milestone consideration paid in shares value				$ 2,354
CHASE Phase 2b clinical trial of KPI-012
Other Commitments
Contingent upon specified development, regulatory and commercialization milestones							$ 175
Combangio, Inc.
Other Commitments
Contingent upon specified development, regulatory and commercialization milestones						$ 40,000
Combangio, Inc. | First patient dosed with any product in phase 2 clinical trial, dosing milestone
Other Commitments
Potential maximum payout for contingent consideration						$ 65,000
Contingent milestone consideration paid		$ 2,500	$ 2,646
Contingent milestone consideration paid in shares value		$ 2,354	$ 2,354
Contingent milestone consideration paid in shares	105,038		105,038
Contingent milestone consideration					$ 146

X

- Definition

Amount of contingent milestone consideration payable in cash in connection with asset acquisition.

+ References

No definition available.

+ Details

Name:	kala_AssetAcquisitionContingentMilestoneConsiderationCashPaid
Namespace Prefix:	kala_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of acquirer's equity interest issued and issuable as part of contingent milestone consideration transferred in asset acquisition.

+ References

No definition available.

+ Details

Name:	kala_AssetAcquisitionContingentMilestoneConsiderationEquityInterestIssuedOrIssuable
Namespace Prefix:	kala_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of shares of acquirer's equity interest issued and issuable as part of contingent milestone consideration transferred in asset acquisition.

+ References

No definition available.

+ Details

Name:	kala_AssetAcquisitionContingentMilestoneConsiderationNumberOfEquityInterestIssuedOrIssuable
Namespace Prefix:	kala_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of contingent milestone consideration in connection with asset acquisition.

+ References

No definition available.

+ Details

Name:	kala_AssetAcquisitionContingentMilestoneConsiderationPayable
Namespace Prefix:	kala_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of potential maximum payout for contingent consideration contingent upon the achievement of specified development, regulatory and sales-based milestones related to specified product.

+ References

No definition available.

+ Details

Name:	kala_PotentialMaximumPayoutForContingentConsideration
Namespace Prefix:	kala_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Potential payout for contingent consideration upon achievement of specified development , regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	kala_PotentialPayoutForContingentConsiderationUponAchievementOfSpecifiedDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	kala_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementScenarioAxis=kala_ChasePhase2ClinicalTrialOfKpi012Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=kala_CombangioIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=kala_FirstPatientDosedWithAnyProductInPhase2ClinicalTrialDosingMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: